EcoDrugPlus

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSVVUG00000004888
Gene Symbol: GRIA1
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSVVUG00000021025
Gene Symbol: GRIA2
3 Cross references
321 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSVVUG00000028161
Gene Symbol: GRIA3
3 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSVVUG00000013946
Gene Symbol: GRIA4
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSVVUG00000029460
Gene Symbol: GRIN1
3 Cross references
278 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSVVUG00000017527
Gene Symbol: GRIN2A
3 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSVVUG00000004606
Gene Symbol: GRIN2B
3 Cross references
330 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSVVUG00000010106
Gene Symbol: GRIN2C
3 Cross references
244 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSVVUG00000023260
Gene Symbol: GRIN2D
3 Cross references
278 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSVVUG00000014824
Gene Symbol: GRIK1
3 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSVVUG00000015421
Gene Symbol: GRIK2
3 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSVVUG00000023178
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).